18:32 , Sep 28, 2018 |  BioCentury  |  Emerging Company Profile

Stopping chain swapping

By controlling how antibody chains pair, Elstar Therapeutics Inc.’s platform can produce multispecific antibodies at yields comparable to methods for manufacturing monospecific antibodies. The company develops multispecific antibodies with up to four functional domains that...
18:46 , Sep 7, 2018 |  BioCentury  |  Emerging Company Profile

Leveraging cross-linking

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs. According to founder and...
18:08 , May 11, 2018 |  BC Week In Review  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed on May 9 to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed...
20:14 , May 10, 2018 |  BC Extra  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
21:32 , Apr 18, 2018 |  BC Extra  |  Preclinical News

Study challenges FCGR2A as latent HIV marker

A paper in...
19:51 , Apr 16, 2018 |  BC Extra  |  Preclinical News

Fate's CAR Ts show efficacy

Fate Therapeutics Inc. (NASDAQ:FATE) presented data Monday at the American Association for Cancer Research meeting in Chicago showing that its off-the-shelf CAR T cell therapy FT819 elicited an immune response in cell studies. FT819 cells...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib/IIa data of AFM13 for cutaneous lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from three evaluable patients with relapsed or refractory CD30-positive, cutaneous lymphoma in the first dose cohort of a Phase Ib/IIa trial showing that once-weekly 1.5 mg/kg IV AFM13 led to...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib data of AFM13 plus Keytruda for Hodgkin's lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from nine evaluable patients with relapsed or refractory Hodgkin's lymphoma in a Phase Ib trial showing that 7 mg/kg IV AFM13 plus anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co....
00:20 , Dec 22, 2017 |  BC Innovations  |  Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...